Literature DB >> 11550309

Cytogenetics and molecular genetics of childhood brain tumors.

J A Biegel1.   

Abstract

Considerable progress has been made toward improving survival for children with brain tumors, and yet there is still relatively little known regarding the molecular genetic events that contribute to tumor initiation or progression. Nonrandom patterns of chromosomal deletions in several types of childhood brain tumors suggest that the loss or inactivation of tumor suppressor genes are critical events in tumorigenesis. Deletions of chromosomal regions 10q, 11 and 17p, and example, are frequent events in medulloblastoma, whereas loss of a region within 22q11.2, which contains the INI1 gene, is involved in the development of atypical teratoid and rhabdoid tumors. A review of the cytogenetic and molecular genetic changes identified to date in childhood brain tumors will be presented.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 11550309      PMCID: PMC1920753          DOI: 10.1093/neuonc/1.2.139

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


  24 in total

Review 1.  Brain tumors and polyomaviruses.

Authors:  Sidney Croul; Jessica Otte; Kamel Khalili
Journal:  J Neurovirol       Date:  2003-04       Impact factor: 2.643

2.  Pharmacological activation of the p53 pathway by nutlin-3 exerts anti-tumoral effects in medulloblastomas.

Authors:  Annette Künkele; Katleen De Preter; Lukas Heukamp; Theresa Thor; Kristian W Pajtler; Wolfgang Hartmann; Michel Mittelbronn; Michael A Grotzer; Hedwig E Deubzer; Frank Speleman; Alexander Schramm; Angelika Eggert; Johannes H Schulte
Journal:  Neuro Oncol       Date:  2012-05-16       Impact factor: 12.300

3.  HDM2 promotes WIP1-mediated medulloblastoma growth.

Authors:  Meghan C Buss; Tracy-Ann Read; Matthew J Schniederjan; Khanjan Gandhi; Robert C Castellino
Journal:  Neuro Oncol       Date:  2012-02-29       Impact factor: 12.300

4.  Primary intracranial atypical teratoid/rhabdoid tumors of infancy and childhood: MRI features and patient outcomes.

Authors:  S P Meyers; Z P Khademian; J A Biegel; S H Chuang; D N Korones; R A Zimmerman
Journal:  AJNR Am J Neuroradiol       Date:  2006-05       Impact factor: 3.825

5.  WIP1 enhances tumor formation in a sonic hedgehog-dependent model of medulloblastoma.

Authors:  Tiffany A Doucette; Yuhui Yang; Carolyn Pedone; John Y H Kim; Adrian Dubuc; Paul D Northcott; Michael D Taylor; Daniel W Fults; Ganesh Rao
Journal:  Neurosurgery       Date:  2012-04       Impact factor: 4.654

Review 6.  Molecular analysis of pediatric brain tumors.

Authors:  Jaclyn A Biegel; Ian F Pollack
Journal:  Curr Oncol Rep       Date:  2004-11       Impact factor: 5.075

7.  Chromosomal heterogeneity and instability characterize pediatric medulloblastoma cell lines and affect neoplastic phenotype.

Authors:  Angel Mauricio Castro-Gamero; Kleiton Silva Borges; Regia Caroline Lira; Augusto Faria Andrade; Paola Fernanda Fedatto; Gustavo Alencastro Veiga Cruzeiro; Ricardo Bonfim Silva; Aparecida Maria Fontes; Elvis Terci Valera; Michael Bobola; Carlos Alberto Scrideli; Luiz Gonzaga Tone
Journal:  Cytotechnology       Date:  2013-01-17       Impact factor: 2.058

8.  Small cell undifferentiated variant of hepatoblastoma: adverse clinical and molecular features similar to rhabdoid tumors.

Authors:  Angela D Trobaugh-Lotrario; Gail E Tomlinson; Milton J Finegold; Lia Gore; James H Feusner
Journal:  Pediatr Blood Cancer       Date:  2009-03       Impact factor: 3.167

9.  Genetic alterations of E-cadherin and beta-catenin in germinoma and teratoma: report of two central nervous system cases.

Authors:  Nives Pećina-Slaus; Tamara Niku Eva-Martić; Vili Beros; Davor Tomas
Journal:  Pathol Oncol Res       Date:  2007-12-25       Impact factor: 3.201

10.  GIN'n'CIN hypothesis of brain aging: deciphering the role of somatic genetic instabilities and neural aneuploidy during ontogeny.

Authors:  Yuri B Yurov; Svetlana G Vorsanova; Ivan Y Iourov
Journal:  Mol Cytogenet       Date:  2009-11-25       Impact factor: 2.009

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.